Saturday 17 October 2026 Export CRMD’s income statement to Excel — free account

CorMedix Inc

CorMedix Inc’s revenue for fiscal 2025 (year ended December 2025) was $311.7 million, up 617.0% from fiscal 2024. In the quarter to June 2026, revenue grew 156.5%, EPS grew 13.8% and free cash flow grew 185.9%, each against the same quarter a year earlier.

7.26 0.20 −2.68%

Follow CRMD

Alert me

Market cap: $581.5M
P/E: 3.0×
Fwd P/E: 16.5×
Dividend yield: —
F-score: n/a
Altman Z: 2.15
Beneish M: 12.80
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 2.64

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	2	5	1	—	—	—	—	—	—	—	—	—

Insider Ownership 8.88%

Capital & Financial Ratios $m

Market Cap 581.47

Revenue 462.25

Net Income 187.17

Free Cash Flow 250.42

Net Debt (111.54)

Current Ratio 2.56

Debt/Equity 0.32

P/E ratio 3.01

Fwd P/E 16.50

P/S ratio 1.23

P/B ratio 1.24

Past 5Y EPS Growth —

This Y EPS Growth (75.74%)

Next Y EPS Growth (88.55%)

Next Y revenue growth 8.15%

Next 5Y EPS Growth (28.23%)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 0.18%

10-year low 10-year high

P/B against its own 10 years 1.51%

10-year low 10-year high

EV/Sales against its own 10 years 0.19%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	76	52	149	257
Receivables	—	52	171	161
Inventory	2	8	30	39
Other	—	—	—	—
	79	115	367	481

	2023	2024	2025	Q'26
Payables	4	2	8	10
ST’ Debt	—	—	—	—
Other	—	—	3	4
	11	34	174	187

Compound Annual Growth %

	10y	5y	3y
Sales	109.73%	305.79%	1,077.55%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	28.12%	55.75%	94.53%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	127	102	—	—	—
’25	39	40	104	129	312
’24	—	1	11	31	43
’22	0	0	0	0	0
’21	0	0	0	0	0
’20	0	0	0	0	0
’19	0	0	0	0	0

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	42	86	—	—	—
’25	20	30	31	94	175
’24	(17)	(14)	(14)	(6)	(51)
’23	(10)	(9)	(9)	(11)	(38)
’22	(7)	(5)	(6)	(6)	(24)
’21	(7)	(3)	(6)	(6)	(21)
’20	(8)	(1)	(7)	(6)	(22)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	42	86	—	—	—
’25	20	30	30	93	173
’24	(17)	(14)	(14)	(6)	(51)
’23	(10)	(9)	(9)	(11)	(39)
’22	(7)	(5)	(6)	(6)	(25)
’21	(7)	(3)	(6)	(6)	(23)
’20	(8)	(1)	(7)	(6)	(22)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	0.43	0.29	—	—	—
’25	0.30	0.28	1.26	0.16	2.04
’24	(0.25)	(0.25)	(0.05)	0.22	(0.30)
’23	(0.24)	(0.25)	(0.17)	(0.26)	(0.91)
’22	(0.18)	(0.19)	(0.17)	(0.20)	(0.74)
’21	(0.20)	(0.12)	(0.22)	(0.20)	(0.75)
’20	(0.21)	(0.14)	(0.22)	(0.19)	(0.77)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	5.75	1.60	0.85	4.86	2.16	4.30	2.65	2.57	2.89	5.60	Analyst estimates 2026–2028 Powerpack
	High	22.70	12.40	12.00	13.70	9.42	18.80	8.03	6.09	13.85	17.43
People
People	Employees	14	14	22	30	35	30	40	83	65	191
	Revenue/emp, $m	0.02	0.02	0.02	0.01	0.01	0.01	0.00	0.00	0.67	1.63
Income, $m
Income, $m	Revenue	0	0	0	0	0	0	0	—	43	312
	Gross margin, %	(63.63)	65.11	7.68	(31.77)	14.38	22.00	94.34	—	92.66	88.46
	EBT	(25)	(33)	(27)	(21)	(27)	(29)	(30)	(46)	(19)	150
	EBT margin, %	(10,996.70)	(10,024.26)	(6,242.35)	(7,586.97)	(11,370.03)	(15,432.37)	(46,310.86)	0.00	(44.45)	48.13
	Net income	(25)	(33)	(27)	(16)	(22)	(28)	(30)	(46)	(18)	163
	Depreciation	0	0	0	0	0	0	0	0	0	15
Per share, $
Per share, $	Revenue	0.03	0.03	0.02	0.01	0.01	0.01	0.00	0.00	0.74	4.33
	Earnings	(3.25)	(3.00)	(1.50)	(1.80)	(0.77)	(0.75)	(0.74)	(0.91)	(0.30)	2.25
	Cash flow	(2.93)	(2.59)	(1.33)	(0.62)	(0.77)	(0.56)	(0.60)	(0.75)	(0.86)	2.43
	Capex	(0.01)	(0.01)	0.00	0.00	0.00	(0.04)	(0.01)	(0.01)	0.00	(0.03)
	Free cash flow	(2.94)	(2.61)	(1.33)	(0.62)	(0.77)	(0.60)	(0.61)	(0.76)	(0.86)	2.40
	Book value	2.35	0.65	0.28	0.98	1.55	1.67	1.37	1.38	1.44	5.63
	Shares, m	8	11	18	24	29	38	40	51	59	72
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—	0.00	5.26
	P/S	289.71	88.72	267.37	620.64	887.19	897.28	2,574.09	—	10.96	2.69
	P/B	3.64	4.06	23.29	7.44	4.80	2.73	3.06	—	5.63	2.07
	EV/Sales	198.96	51.82	240.22	519.95	696.40	558.04	1,683.43	—	9.79	2.68
	EV/FCF	(2.00)	(0.59)	(4.35)	(9.76)	(7.54)	(4.72)	(4.48)	—	(8.39)	4.83
Cash, $m
Cash, $m	Operating cash flow	(22)	(29)	(24)	(15)	(22)	(21)	(24)	(38)	(51)	175
	Capex	0	0	0	0	0	(1)	0	0	0	(2)
	Free cash flow	(22)	(29)	(24)	(15)	(22)	(23)	(25)	(39)	(51)	173
Balance, $m
Balance, $m	Working capital	18	7	11	24	44	61	53	68	81	193
	Total debt	—	—	6	0	1	1	1	—	—	145
	Net debt	(20)	(12)	(12)	(29)	(46)	(65)	(58)	(76)	(52)	(3)
	Shareholders’ equity	18	7	5	24	44	63	55	70	85	405
Returns, %
Returns, %	ROA	(83.53)	(186.71)	(166.23)	(180.27)	(55.92)	(47.71)	(45.35)	(64.32)	(17.85)	34.51
	ROIC	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	(42.38)	23.34
	ROE	(95.10)	(264.01)	(442.49)	(304.66)	(64.91)	(52.72)	(50.40)	(74.02)	(23.17)	66.56

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ZVRA Zevra Therapeutics, Inc.	$609.9M	10.5×	10.5×	+53.25% (above 0%: growing)	−88.71% (below 0%: shrinking)	+670.87% (above 0%: growing)	96.16%	42.30%	Compare
PHAT Phathom Pharmaceuticals, Inc.	$606.8M	— (loss-making)	— (loss-making)	+88.02% (above 0%: growing)	n/m	+96.86% (above 0%: growing)	79.68%	(5.34%)	Compare
OLMA Olema Pharmaceuticals, Inc.	$601.1M	— (loss-making)	—	—	n/m	−54.33% (below 0%: shrinking)	0.00%	0.00%	Compare
CRMD CorMedix Inc	$581.5M	3.0×	16.5×	+156.52% (above 0%: growing)	+13.79% (above 0%: growing)	+185.90% (above 0%: growing)	75.66%	42.10%
SLN Silence Therapeutics PLC Sponsored ADR	$581.1M	— (loss-making)	— (loss-making)	+197.18% (above 0%: growing)	n/m	+106.95% (above 0%: growing)	97.39%	0.00%	Compare
SGMT Sagimet Biosciences Inc.	$574.7M	— (loss-making)	— (loss-making)	—	n/m	−21.95% (below 0%: shrinking)	100.00%	0.00%	Compare
DBVT DBV Technologies S.A.	$572.6M	— (loss-making)	—	−53.33% (below 0%: shrinking)	n/m	−56.15% (below 0%: shrinking)	100.00%	(7,228.57%)	Compare
VALN Valneva SE Sponsored ADR	$560.4M	59.7×	19.4×	−17.29% (below 0%: shrinking)	n/m	−56.05% (below 0%: shrinking)	15.29%	(76.67%)	Compare
STTK Shattuck Labs, Inc.	$555.0M	— (loss-making)	— (loss-making)	−10.31% (below 0%: shrinking)	n/m	+1.01% (above 0%: growing)	100.00%	0.00%	Compare
Median of peers	$577.9M	—	—	+21.47%	—	−10.47%	96.78%	0.00%

All 614 Biotechnology stocks →

CorMedix Inc (CRMD) key facts

Strength: CorMedix Inc’s revenue for fiscal 2025 (year ended December 2025) was $311.7 million, up 617.0% from fiscal 2024.
CorMedix Inc (CRMD) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, CRMD traded at $7.26, a market capitalization of $581.5 million.
Return on equity was 66.6% and debt-to-equity 0.32.
Its Altman Z-score is 2.15 (grey zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.